From a sprawling study of nearly 40,000 South African children to the bedside of pregnant mothers receiving flu shots, Professor Shabir A. Madhi has spent decades reshaping how the world protects its most vulnerable populations from infectious disease. Now, the University of the Witwatersrand researcher has been recognised with the 2026 Maxwell Finland Award for Scientific Achievement, one of the world's most prestigious honours in infectious disease research, cementing South Africa's position at the forefront of global vaccine innovation.
The National Foundation for Infectious Diseases, a leading US-based public health organisation, announced the award to Madhi in recognition of his pioneering work that has directly informed international immunisation policies and saved hundreds of thousands of lives. What makes this recognition particularly significant is that much of his most influential research has been conducted not in wealthy research capitals, but in Africa's highest-burden settings—places where infectious diseases claim the most lives and where evidence is often scarcest.
Madhi's contributions span the full lifecycle of vaccine development and policy. His landmark South African trial demonstrated the effectiveness of pneumococcal conjugate vaccines in protecting children against pneumococcal infections and pneumonia, generating evidence that reshaped scientific understanding of how respiratory viruses interact with bacterial pathogens. Today, those vaccines alone are estimated to have prevented hundreds of thousands of child deaths globally. In parallel work on rotavirus vaccines, Madhi generated the evidence base that informed global health recommendations for low- and middle-income countries, where diarrhoeal disease remains a leading killer of children.
Perhaps most innovatively, Madhi pioneered maternal vaccination research that the world had largely overlooked. He led the first-ever randomised controlled trial of influenza vaccination in pregnant women, demonstrating protection for both mothers and their newborns—opening an entirely new frontier in infectious disease prevention. His subsequent groundbreaking research into maternal vaccines against respiratory syncytial virus and Group B Streptococcus continues to expand what's possible in protecting infants before they're even born.
When the COVID-19 pandemic struck, Madhi again placed South Africa at the centre of global scientific response by leading Africa's first SARS-CoV-2 vaccine trials. The research provided critical early evidence that shaped vaccine policy and public health responses during the most urgent public health crisis in a generation.
Orin S. Levine, president and chief executive officer of the Washington Research Foundation, captured the essence of Madhi's legacy: "His career reflects the highest ideals of the Maxwell Finland Award: rigorous science, visionary leadership, and lasting global impact on infectious disease prevention."
Beyond his own research, Madhi has mentored a generation of vaccinologists and infectious disease researchers across Africa, strengthening the continent's capacity to conduct world-class science and respond to its own public health crises. He will formally receive the award at the NFID Awards Gala in Washington, DC, on 20 October 2026, joining fellow honourees including Dr Richard J. Hatchett of the Coalition for Epidemic Preparedness Innovations and Dr Kathleen M. Neuzil of the Gates Foundation's polio programme.